For U.S. Healthcare Professionals

Patient journey to diagnosis and living with PAH

Kathy is a real patient with PAH. Her photos were used to create a unique collage that shows the pieces of her life and who she is as an individual, and not just a patient with PAН.

Individual patient experience may vary. OPSUMIT® has a 9-year long-term safety, tolerability, and survival open-label extension study in patients with PAH.1

Patient profile: Kathy collage artwork

Kathy
Aspiring author
OPSUMIT® patient since 2019

Kathy is an animal lover and mother of 3. Before her PAH diagnosis, she enjoyed playing racquetball, studied laboratory animal science in college, and became a pet groomer.

In 2011, after several unusual medical experiences and misdiagnoses, it was discovered that she had an autoimmune condition, scleroderma. In late 2012, her rheumatologist noticed that her chest X-rays and MRI scan revealed an enlarged heart. Her rheumatologist referred her to a cardiologist who suspected the scleroderma had led to PAH, which was confirmed by an RHC.

In addition to other medication, Kathy began taking OPSUMIT® in 2019. “It gives me that inner peace knowing right now that I’m stable and can function...” These days, she enjoys encouraging other patients with PAH to be strong and find a support group. Kathy sits on the board of a pulmonary fibrosis support group and is also active in advocacy organizations. She is currently writing a memoir of her PAH experience.

Individual patient experiences may vary.

About the artist

Patrick Bremer is a creative from the UK chosen by Johnson & Johnson to reimagine a campaign focused around how starting with the right foundational therapy impacts a patient’s life. As an artist who specializes in creating striking collages, he has been commissioned in the past by the likes of Google, The New Yorker, and AARP. Patrick’s unique portraiture style brings to life the pieces of a patient’s world and connects it to their experience with OPSUMIT®.

BACK TO TOP

MRI=magnetic resonance imaging; PAH=pulmonary arterial hypertension; RHC=right heart catheterization.
Reference: 1. Souza R, Delcroix M, Galié N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39(9):4374-4390

EXPAND +

+ +